Comera Life Sciences announces publication of study on caffeine

Comera Life Sciences announced the peer-reviewed publication of preclinical data in the Journal of Pharmaceutical Sciences, which provide further evidence of caffeine’s viscosity reducing capabilities and support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies. These studies aimed to assess the pharmacokinetic characteristics of caffeine and its influence on the PK behavior of a representative monoclonal antibody ipilimumab. The outcomes show rapid SQ absorption and elimination of caffeine, regardless of whether it was administered alone or in conjunction with the monoclonal antibody. Notably, caffeine exhibited no impact on the PK profiles of ipilimumab with SQ administration. “Comera continues to innovate on the delivery of biologic medicines and this publication reflects our extensive expertise in solving some of the most challenging problems in protein engineering,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. “These insights bring us closer to delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines. We look forward to continuing the development of caffeine as a viscosity reducing agent for subcutaneous monoclonal antibody formulations, while also embarking on the expansion of our computational modeling tools to potentially include cutting-edge AI capabilities.”